Mobile

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Dacarbazine versus Dacarbazine Alone as First Line Therapy in Patients with Stage IV Melanoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-016049-24

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• Phase Ib: to define the safety, tolerability and maximum tolerated dose (MTD) of E7080 administered in combination with dacarbazine in patients with Stage IV melanoma. • Phase II: to evaluate the safety and tolerability of E7080 administered in combination with dacarbazine, compared with dacarbazine alone, in patients with Stage IV melanoma.

Critère d'inclusion

  • Stage IV Melanoma

Liens